Course Description
With the FDA’s REMS program removed, the responsibility for clozapine monitoring now lies fully with clinicians. This session covers the rationale for ANC monitoring, practical strategies for managing neutropenia, and how to adjust to post-REMS requirements. Learn how to maintain patient safety while minimizing unnecessary barriers and stay ahead of regulatory changes with up-to-date, practical guidance.
This is one of seven modules in the A New Era in Clozapine Management educational series. Complete your complimentary registration now to access this module and 6 other ACPE, AMA, ANCC, and AAPA accredited modules.
Target Audience
We invite you to participate in this online course if you are a pharmacist, physician, nurse practitioner, physician assistant, nurse, or other health care professional involved in the care of individuals with serious mental illness.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Complete the pre-test (if applicable) before starting the activity.
- Review the full content of the activity and reflect upon its teachings.
- Complete the post-test at the end of the activity no later than the closing activity date.
- Complete the evaluation at the end of the activity.
- If necessary, complete the post-test retest no later than the closing activity date.
- Receive a passing grade (70%).
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
- Explain the rationale for ANC monitoring and its role in clozapine safety.
- Identify strategies for managing neutropenia in clozapine-treated patients.
- Discuss changes in clinical practice following the removal of the REMS program.